THAR (Tharimmune, Inc.) Pangali Forward P/E
The forward P/E ratio of Tharimmune, Inc. (THAR) reflects the current market valuation, where the value of 0.00 expresses the metric level. This trend is driven by the R&D stage and the potential for formula licensing. Growth is supported by a hybrid immunotherapy model and digital assets of the Canton network. Process stability is guaranteed by a streamlined express delivery system for biocomponents, which minimizes logistical disruptions during drug development.
Ringkesan rincian data analitis Tharimmune (THAR)
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- informasi kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Tharimmune, Inc.|THAR - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Tharimmune, Inc.|THAR - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Tharimmune|THAR - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Tharimmune|Likuiditas cepet tharimmune.com
- rincian asil keuangan lan kelipatan valuasi:
THAR - Bathi pungkasan|Proyeksi bathi mangsa ngarep Tharimmune, Inc.|THAR - Periode bali modal bisnis|Rega marang bathi mangsa ngarep tharimmune.com|THAR - Pangali rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Tharimmune|THAR - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Tharimmune|THAR - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan tharimmune.com|THAR - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Tharimmune, Inc.
- indikator volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:Tharimmune Corp
Patents for nanobodies targeting inflammatory skin diseases create a high barrier to entry, protecting the market share of Tharimmune, Inc. (THAR) from competitors. By analyzing the company's forward P/E ratio, an investor can see the relationship between the current share price and expected earnings, which allows for an assessment of the premium paid for future growth and the determination of the fair value of capital over time.
Pesaing langsung
Pangali Forward P/E ONC|HALO (Halozyme Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (revmed.com)|AAPG - Prakiraan rega marang bathi|CGON: Prakiraan rega marang bathi|URGN - Pangali Forward P/E|Bicara Bio (BCAX) - Rega marang bathi mangsa ngarep|Personalis Corp - Pangali mangsa ngarep rega marang bathi|ERAS (Erasca Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Delcath Systems, Inc. DCTH|Prakiraan rega marang bathi YMAB (Y-mAbs Corp)|Pangali Forward P/E Aura Bio (AURA)|Pangali Forward P/E CADL (Candel Therapeutics Inc.)|ARAY - Prakiraan rega marang bathi|SLS - Rega marang bathi mangsa ngarep|Actuate Therapeutics - Rasio kapitalisasi marang bathi mangsa ngarep|CTOR: Pangali Forward P/E|TuHURA (HURA) - Pangali Forward P/E|TARA (Protara Therapeutics Inc) - Pangali Forward P/E|FATE: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E WHWK|TCRX (TScan) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Champions Oncology, Inc. CSBR|XBIT - Prakiraan rega marang bathi|CEL-SCI - Pangali Forward P/E|OSTX - Pangali Forward P/E|Radiopharm Theranostics Limited (RADX) - Rega marang bathi mangsa ngarep|ARTV - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi ANL|Rega marang bathi mangsa ngarep VERU|Pangali Forward P/E TPST|XLO: Rasio rega marang bathi sing dikarepake|Pangali Forward P/E RENB (Renovaro Inc.)|Mural Bio (MURA) - Rasio prakiraan rega marang bathi|Kairos Pharma Ltd - Pangali Forward P/E|Rasio rega marang bathi sing dikarepake OKUR|CytoMed Therapeutics Limited (GDTC) - Rega marang bathi mangsa ngarep|CRIS - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi APLM|Rasio rega marang bathi mangsa ngarep ADVB (Advanced Biomed)|Prakiraan rega marang bathi GNPX (Genprex, Inc)|CLDI: Rasio rega marang bathi sing dikarepake|Rega marang bathi mangsa ngarep sunshinebiopharma.com SBFM|XBIO - Prakiraan rega marang bathi|SLRX: Prakiraan rega marang bathi|Purple Biotech - Rasio kapitalisasi marang bathi mangsa ngarep|American Oncology Network (AONC) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep BGNE|Prakiraan rega marang bathi CKPT|Rega marang bathi mangsa ngarep ELEV|Pangali Forward P/E ICAD|Pangali Forward P/E Ikena Oncology Inc. (IKNA)|Pangali Forward P/E NTBL (Notable Labs Ltd)|Kapitalisasi marang proyeksi bathi Viracta Therapeutics (VIRX)|MOR: Prakiraan rega marang bathi|NAYA (NAYA Bio) - Rasio rega marang bathi mangsa ngarep|AAPGV: Pangali Forward P/E
